Summary
Shares of Novo Nordisk, the company that makes the weight-loss drug Wegovy, dropped by 18% after the firm announced steep price cuts. The company's CEO, Maziar Mike Doustdar, mentioned that the price cuts, driven by a deal with the U.S. government under President Trump, were necessary to make the drugs more accessible but would initially hurt profits. In the U.S., these drugs, used to treat obesity, have high demand but face competition and challenges due to patent expiries.
Key Facts
- Novo Nordisk's shares fell by 18% following announced price cuts for its weight-loss drug Wegovy.
- The company expects a drop in profits and sales by up to 13%.
- The price cuts are part of a deal with President Trump to lower costs for American users.
- Increased competition and patent expirations are affecting Novo Nordisk's profits.
- Weight-loss drugs like Wegovy are popular, which has led to a need for price reductions.
- President Trump announced a policy to reduce the cost of these drugs in the U.S.
- The price for some of these drugs in the U.S. is over $1,000 without discounts or insurance.
